Analysts’ Weekly Ratings Changes for Bausch + Lomb (BLCO)

A number of firms have modified their ratings and price targets on shares of Bausch + Lomb (NYSE: BLCO) recently:

• 2/23/2026 – Bausch + Lomb had its price target raised by analysts at HC Wainwright from $17.00 to $20.00. They now have a “buy” rating on the stock.
• 2/21/2026 – Bausch + Lomb was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 2/19/2026 – Bausch + Lomb was given a new $16.00 price target on by analysts at Stifel Nicolaus.
• 2/19/2026 – Bausch + Lomb had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $18.00 price target on the stock.
• 2/19/2026 – Bausch + Lomb had its price target raised by analysts at Citigroup Inc. from $20.00 to $21.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Bausch + Lomb had its price target raised by analysts at Barclays PLC from $17.00 to $20.00. They now have an “equal weight” rating on the stock.
• 2/19/2026 – Bausch + Lomb had its price target raised by analysts at Wells Fargo & Company from $17.00 to $18.00. They now have an “equal weight” rating on the stock.
• 2/17/2026 – Bausch + Lomb had its price target raised by analysts at Stifel Nicolaus from $14.00 to $15.00. They now have a “hold” rating on the stock.
• 1/27/2026 – Bausch + Lomb had its price target raised by analysts at Royal Bank Of Canada from $19.00 to $21.00. They now have an “outperform” rating on the stock.
• 1/21/2026 – Bausch + Lomb had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/9/2026 – Bausch + Lomb had its “neutral” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $19.00 price target on the stock.
• 1/5/2026 – Bausch + Lomb was given a new $18.00 price target on by analysts at Evercore Inc. They now have an “in-line” rating on the stock.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.